🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. AMG 193, AMG 193, AMG 193

    Amgen

    Advanced MTAP-null solid tumors

    phase 2 small molecule active

    1 trial

  2. AMG 193, IDE397, AMG 193, IDE397, AMG 193

    Amgen

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. AMG 732

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  4. AMINOHIPPURIC ACID, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Felzartamab

    Istituto Gentili S.r.l.

    Membranous nephropathy

    phase 2 small molecule active

    1 trial

  5. AMPHOTERICIN B , VANCOMYCIN , Gentamicin_APHP

    Pari Pharma GmbH

    Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission

    phase 2 small molecule active

    1 trial

  6. AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY IN PARTICIPANTS TREATED WITH CRN04894

    Lacuna Pharma Pty Ltd

    CONGENITAL ADRENAL HYPERPLASIA

    phase 2 other active

    1 trial

  7. ANAKINRA

    Disc Medicine

    Intracerebral haemorrhage

    phase 2 small molecule active

    1 trial

  8. APG777

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    3 trials

  9. APG777, Placebo

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  10. APL-3007, pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 2 small molecule active

    1 trial

  11. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome With Gene Mutation

    phase 2 small molecule active

    1 trial

  12. APREPITANT, IDARUBICIN HYDROCHLORIDE, LEVOCARNITINE, CYCLOPHOSPHAMIDE, GRANISETRON, SALBUTAMOL, GANCICLOVIR, AMPHOTERICIN B, ALLOPURINOL, DARZALEX 1800 mg solution for injection, HUMAN FIBRINOGEN, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, VINCRISTINE SULFATE, PARACETAMOL, MONTELUKAST, FILGRASTIM, CYTARABINE, LEVOFLOXACIN, RASBURICASE, METHOTREXATE, HYDROCORTISONE, FOSCARNET, METHYLPREDNISOLONE SODIUM SUCCINATE, LENOGRASTIM, PEGASPARGASE, DEXAMETHASONE SODIUM PHOSPHATE, MICAFUNGIN, ACICLOVIR, CHLORPHENAMIN

    Fondazione Telethon ETS

    Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  13. ARD-101

    Ark Therapeutics

    Bariatric Surgery

    phase 2 small molecule completed

    1 trial

  14. ARGX-117, ARGX-113

    argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  15. ARICEPT 10mg comprimidos recubiertos con película

    The George Institute

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  16. ARO-RAGE

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma

    phase 2 small molecule active

    2 trials

  17. ART0380, ART0380, GEMCITABINE , ART0380, IRINOTECAN , ART0380

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Solid Tumours

    phase 2 small molecule active

    1 trial

  18. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  19. ASP3082, DEXTROSE INJECTION / BRADEX 5%

    The George Institute

    Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. ASP8951, Calcium Folinate 10 mg/ml Injection, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Fluorouracil 50mg/ml Injection., OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.

    Astellas Pharma GmbH

    Advanced cancer of the stomach or the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  21. ASP8951, PACLITAXEL, GEMCITABINE

    Astellas Pharma GmbH

    First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.

    phase 2 small molecule active

    1 trial

  22. AST-OPC1

    Lineage Cell Therapeutics

    Cervical Spinal Cord Injury

    phase 2 mab completed

    1 trial

  23. ATEZOLIZUMAB

    The George Institute

    Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)

    phase 2 small molecule active

    1 trial

  24. ATI-50002

    Aclaris Therapeutics

    Androgenetic Alopecia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources